Syncona (SYNC) Q1 2026 TU earnings summary

Executive summary

• Net assets stood at £1,045.4 million as of 30 June 2025, with a NAV per share return of 0.5% for the quarter.

• Life science portfolio valued at £774.0 million, up 1.0% from the previous quarter, driven by appreciation in Autolus' share price and Beacon's clinical progress.

• Portfolio includes one commercial-stage and seven clinical-stage companies, with two more expected to reach clinical stage within 12 months.

• Ten key value inflection points targeted over the next three years, aiming for significant NAV growth through M&A and liquidity events.

Financial highlights

• Life science portfolio increased by £8.6 million quarter-over-quarter, reflecting positive clinical and market developments.

• Capital pool at £271.4 million, with £6.6 million deployed during the quarter.

• NAV per share rose to 171.8p from 170.9p at the end of March 2025.

Outlook and guidance

• Ongoing engagement with shareholders regarding strategic proposals, with an update expected in September.

• Portfolio is funded to deliver on 10 key value inflection points over the next three years.